Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer.

Autor: Gunasekharan V; Yale Cancer Center, Yale School of Medicine, 300 George Street, Suite 120, Rm 133, New Haven, CT, 06511, USA., Lin HK; Yale Cancer Center, Yale School of Medicine, 300 George Street, Suite 120, Rm 133, New Haven, CT, 06511, USA., Marczyk M; Yale Cancer Center, Yale School of Medicine, 300 George Street, Suite 120, Rm 133, New Haven, CT, 06511, USA.; Department of Data Science and Engineering, Silesian University of Technology, Gliwice, Poland., Rios-Hoyo A; Yale Cancer Center, Yale School of Medicine, 300 George Street, Suite 120, Rm 133, New Haven, CT, 06511, USA., Campos GE; Yale Cancer Center, Yale School of Medicine, 300 George Street, Suite 120, Rm 133, New Haven, CT, 06511, USA., Shan NL; Yale Cancer Center, Yale School of Medicine, 300 George Street, Suite 120, Rm 133, New Haven, CT, 06511, USA., Ahmed M; Atomwise, San Francisco, CA, USA., Umlauf S; Yale Center for Molecular Discovery, Yale University, West Haven, CT, USA., Gareiss P; Yale Center for Molecular Discovery, Yale University, West Haven, CT, USA., Raaisa R; Yale Cancer Center, Yale School of Medicine, 300 George Street, Suite 120, Rm 133, New Haven, CT, 06511, USA., Williams R; Yale Cancer Center, Yale School of Medicine, 300 George Street, Suite 120, Rm 133, New Haven, CT, 06511, USA., Cardone R; Yale Cancer Center, Yale School of Medicine, 300 George Street, Suite 120, Rm 133, New Haven, CT, 06511, USA., Siebel S; Yale Cancer Center, Yale School of Medicine, 300 George Street, Suite 120, Rm 133, New Haven, CT, 06511, USA., Kibbey R; Yale Cancer Center, Yale School of Medicine, 300 George Street, Suite 120, Rm 133, New Haven, CT, 06511, USA., Surovtseva YV; Yale Center for Molecular Discovery, Yale University, West Haven, CT, USA., Pusztai L; Yale Cancer Center, Yale School of Medicine, 300 George Street, Suite 120, Rm 133, New Haven, CT, 06511, USA. lajos.pusztai@yale.edu.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Dec; Vol. 208 (3), pp. 657-671. Date of Electronic Publication: 2024 Aug 23.

Atypical Asparagine Deamidation of NW Motif Significantly Attenuates the Biological Activities of an Antibody Drug Conjugate.

Autor: Cao M; Department of Process and Analytical Sciences, Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD 20878, USA., Hussmann GP; Department of Process and Analytical Sciences, Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD 20878, USA., Tao Y; Department of Process and Analytical Sciences, Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD 20878, USA., O'Connor E; Department of Process and Analytical Sciences, Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD 20878, USA., Parthemore C; Department of Process and Analytical Sciences, Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD 20878, USA., Zhang-Hulsey D; Department of Process and Analytical Sciences, Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD 20878, USA., Liu D; Department of Process and Analytical Sciences, Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD 20878, USA., Jiao Y; Department of Process and Analytical Sciences, Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD 20878, USA., Mel N; Department of Process and Analytical Sciences, Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD 20878, USA., Prophet M; Department of Process and Analytical Sciences, Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD 20878, USA., Korman S; Department of Process and Analytical Sciences, Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD 20878, USA., Sonawane J; Department of Process and Analytical Sciences, Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD 20878, USA., Grigoriadou C; Department of Process and Analytical Sciences, Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD 20878, USA., Huang Y; Department of Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, 121 Oyster Point Boulevard, South San Francisco, CA 94080, USA., Umlauf S; Department of Process and Analytical Sciences, Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD 20878, USA., Chen X; Department of Process and Analytical Sciences, Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD 20878, USA.

Publikováno v: Antibodies (Basel, Switzerland) [Antibodies (Basel)] 2023 Oct 24; Vol. 12 (4). Date of Electronic Publication: 2023 Oct 24.

Comprehensive Analysis of Metabolic Isozyme Targets in Cancer.

Autor: Marczyk M; Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut.; Department of Data Science and Engineering, Silesian University of Technology, Gliwice, Poland., Gunasekharan V; Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut., Casadevall D; Cancer Research Program, Hospital del Mar Research Institute (IMIM), Barcelona, Spain.; Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, Madrid, Spain., Qing T; Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut., Foldi J; Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut., Sehgal R; Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut., Shan NL; Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut., Blenman KRM; Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut., O'Meara TA; Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut., Umlauf S; Yale Center for Molecular Discovery, Yale University, West Haven, Connecticut., Surovtseva YV; Yale Center for Molecular Discovery, Yale University, West Haven, Connecticut., Muthusamy V; Center for Precision Cancer Modeling, Yale School of Medicine, New Haven, Connecticut., Rinehart J; Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut., Perry RJ; Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut., Kibbey R; Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut., Hatzis C; Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut., Pusztai L; Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut.

Publikováno v: Cancer research [Cancer Res] 2022 May 03; Vol. 82 (9), pp. 1698-1711.

ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome.

Autor: Baker AT; Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ 85054, USA.; Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.; Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA.; Mayo Clinic Cancer Center, Phoenix, AZ 85054, USA.; Biodesign Center for Applied Structural Discovery, Arizona State University, Tempe, AZ 85281, USA.; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK., Boyd RJ; Biodesign Center for Applied Structural Discovery, Arizona State University, Tempe, AZ 85281, USA.; School of Molecular Sciences, Arizona State University, Tempe, AZ 85251, USA., Sarkar D; School of Molecular Sciences, Arizona State University, Tempe, AZ 85251, USA.; MSU-DOE Plant Research Laboratory, Michigan State University, East Lansing, MI 48824.; Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824., Teijeira-Crespo A; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK., Chan CK; Computational Structural Biology and Molecular Biophysics, Beckman institute, University of Illinois, IL 61801, USA., Bates E; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK., Waraich K; Institute of Infection Immunity and Inflammation, MRC-University of Glasgow Centre for Virus Research, Glasgow G61 1QH, UK., Vant J; Biodesign Center for Applied Structural Discovery, Arizona State University, Tempe, AZ 85281, USA.; School of Molecular Sciences, Arizona State University, Tempe, AZ 85251, USA., Wilson E; Biodesign Center for Applied Structural Discovery, Arizona State University, Tempe, AZ 85281, USA.; School of Molecular Sciences, Arizona State University, Tempe, AZ 85251, USA., Truong CD; Biodesign Center for Applied Structural Discovery, Arizona State University, Tempe, AZ 85281, USA.; School of Molecular Sciences, Arizona State University, Tempe, AZ 85251, USA., Lipka-Lloyd M; Medicines Discovery Institute, School of Biosciences, Cardiff University, Cardiff CF10 3AT, UK., Fromme P; Biodesign Center for Applied Structural Discovery, Arizona State University, Tempe, AZ 85281, USA.; School of Molecular Sciences, Arizona State University, Tempe, AZ 85251, USA., Vermaas J; MSU-DOE Plant Research Laboratory, Michigan State University, East Lansing, MI 48824.; Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824., Williams D; Eyring Materials Center, Arizona State University, Tempe, AZ 85281, USA., Machiesky L; Analytical Sciences, Biopharmaceutical Development, AstraZeneca, Gaithersburg, MD 20878, USA., Heurich M; School of Pharmacy and Pharmaceutical Science, College of Biomedical and Life Sciences, Cardiff University, Cardiff CF10 3NB, UK., Nagalo BM; Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ 85054, USA.; Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.; Mayo Clinic Cancer Center, Phoenix, AZ 85054, USA., Coughlan L; Department of Microbiology and Immunology, University of Maryland School of Medicine, 685 W. Baltimore Street, MD 21201, USA.; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore Street, MD 21201, USA., Umlauf S; Analytical Sciences, Biopharmaceutical Development, AstraZeneca, Gaithersburg, MD 20878, USA., Chiu PL; Biodesign Center for Applied Structural Discovery, Arizona State University, Tempe, AZ 85281, USA.; School of Molecular Sciences, Arizona State University, Tempe, AZ 85251, USA., Rizkallah PJ; Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK., Cohen TS; Microbial Sciences, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA., Parker AL; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK., Singharoy A; Biodesign Center for Applied Structural Discovery, Arizona State University, Tempe, AZ 85281, USA.; School of Molecular Sciences, Arizona State University, Tempe, AZ 85251, USA., Borad MJ; Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ 85054, USA.; Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.; Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA.; Mayo Clinic Cancer Center, Phoenix, AZ 85054, USA.

Publikováno v: Science advances [Sci Adv] 2021 Dec 03; Vol. 7 (49), pp. eabl8213. Date of Electronic Publication: 2021 Dec 01.

Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells.

Autor: Pandey MS; Bioassay Development, Analytical Sciences, Biopharmaceutical Development, R&D, AstraZeneca, Gaithersburg, MD 20878, USA., Wang C; Physicochemical-Analytical Sciences, Biopharmaceutical Development, AstraZeneca, R&D, Gaithersburg, MD 20878, USA., Umlauf S; Bioassay Development, Analytical Sciences, Biopharmaceutical Development, R&D, AstraZeneca, Gaithersburg, MD 20878, USA., Lin S; Bioassay Development, Analytical Sciences, Biopharmaceutical Development, R&D, AstraZeneca, Gaithersburg, MD 20878, USA.

Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2021 Oct 21; Vol. 22 (21). Date of Electronic Publication: 2021 Oct 21.